To the Editor: I am surprised that the target systolic bloodpressures in three studies of the renoprotective effects ofangiotensin-receptor blockers in patients with type 2 diabetes(Sept. 20 issue)1,2,3 exceeded the threshold of less than 130mm Hg recommended in the sixth report of the Joint NationalCommittee on Prevention, Detection, Evaluation, and Treatmentof High Blood Pressure (JNC-VI).4 After treatment, the meansystolic blood pressure for all treatment groups in each studywas 140 mm Hg or higher. What kind of example is this for practicingphysicians who treat hypertensive patients with diabetes?
Chiarelli, F., Di Marzio, D., Santilli, F., Mohn, A., Blasetti, A., Cipollone, F., Mezzetti, A., Verrotti, A.
(2005). Effects of Irbesartan on Intracellular Antioxidant Enzyme Expression and Activity in Adolescents and Young Adults With Early Diabetic Angiopathy. Diabetes Care
28: 1690-1697
[Abstract][Full Text]
Ceriello, A., Assaloni, R., Da Ros, R., Maier, A., Piconi, L., Quagliaro, L., Esposito, K., Giugliano, D.
(2005). Effect of Atorvastatin and Irbesartan, Alone and in Combination, on Postprandial Endothelial Dysfunction, Oxidative Stress, and Inflammation in Type 2 Diabetic Patients. Circulation
111: 2518-2524
[Abstract][Full Text]
Ceriello, A., Motz, E.
(2004). Is Oxidative Stress the Pathogenic Mechanism Underlying Insulin Resistance, Diabetes, and Cardiovascular Disease? The Common Soil Hypothesis Revisited. Arterioscler. Thromb. Vasc. Bio.
24: 816-823
[Abstract][Full Text]
Alter, D. A., Khaykin, Y., Austin, P. C., Tu, J. V., Hux, J. E.
(2003). Processes and Outcomes of Care for Diabetic Acute Myocardial Infarction Patients in Ontario: Do physicians undertreat?. Diabetes Care
26: 1427-1434
[Abstract][Full Text]
Ceriello, A.
(2003). New Insights on Oxidative Stress and Diabetic Complications May Lead to a "Causal" Antioxidant Therapy. Diabetes Care
26: 1589-1596
[Abstract][Full Text]